Square Pharmaceuticals PLC. (DSE:SQURPHARMA)

DSE:SQURPHARMA Income Statement

Financials in millions BDT. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Revenue	75,860	70,101	60,708	57,598	50,703	45,876
Revenue Growth (YoY)	17.34%	15.47%	5.40%	13.60%	10.52%	4.18%
Cost of Revenue	41,847	37,957	32,473	28,719	25,470	23,141
Gross Profit	34,013	32,144	28,235	28,879	25,233	22,736
Selling, General & Admin	15,837	14,168	11,689	12,118	10,034	8,855
Other Operating Expenses	-417.46	-199.9	-144.4	-98.27	-69.57	10.79
Operating Expenses	15,420	13,968	11,545	12,019	9,965	8,865
Operating Income	18,593	18,176	16,690	16,860	15,269	13,870
Interest Expense	-249.09	-244	-118.97	-0.03	-0.01	-0.11
Interest & Investment Income	5,823	4,651	3,957	3,004	3,137	2,965
Earnings From Equity Investments	3,451	2,595	2,523	2,011	1,291	586.24
Currency Exchange Gain (Loss)	346.52	346.52	650.1	451.34	19.42	-0.7
Other Non Operating Income (Expenses)	-	-	-	-	34.43	33.62
EBT Excluding Unusual Items	27,964	25,524	23,701	22,325	19,751	17,455
Gain (Loss) on Sale of Investments	99.12	-	-	384.59	177.04	100.09
Gain (Loss) on Sale of Assets	-208	-208	-79.8	53.49	-	28.38
Other Unusual Items	0.26	0.26	0.62	0.72	32.06	-
Pretax Income	27,855	25,316	23,622	22,764	19,960	17,583
Income Tax Expense	4,349	4,389	4,642	4,607	4,013	4,229
Earnings From Continuing Operations	23,506	20,927	18,980	18,157	15,947	13,354
Minority Interest in Earnings	-2.62	-1.61	-0.24	0.03	-	-
Net Income	23,503	20,926	18,980	18,157	15,947	13,354
Net Income to Common	23,503	20,926	18,980	18,157	15,947	13,354
Net Income Growth	16.13%	10.25%	4.53%	13.86%	19.42%	5.60%
Shares Outstanding (Basic)	886	886	886	886	886	886
Shares Outstanding (Diluted)	886	886	886	886	886	886
EPS (Basic)	26.51	23.61	21.41	20.48	17.99	15.06
EPS (Diluted)	26.51	23.61	21.41	20.48	17.99	15.06
EPS Growth	16.13%	10.25%	4.53%	13.86%	19.42%	5.60%
Free Cash Flow	8,193	14,348	5,685	6,692	7,178	8,718
Free Cash Flow Per Share	9.24	16.18	6.41	7.55	8.10	9.84
Dividend Per Share	11.000	11.000	10.500	10.000	6.000	4.476
Dividend Growth	4.76%	4.76%	5.00%	66.67%	34.04%	19.74%
Gross Margin	44.84%	45.85%	46.51%	50.14%	49.77%	49.56%
Operating Margin	24.51%	25.93%	27.49%	29.27%	30.11%	30.23%
Profit Margin	30.98%	29.85%	31.26%	31.52%	31.45%	29.11%
Free Cash Flow Margin	10.80%	20.47%	9.37%	11.62%	14.16%	19.00%
EBITDA	20,800	20,495	19,000	18,695	17,151	15,791
EBITDA Margin	27.42%	29.24%	31.30%	32.46%	33.83%	34.42%
D&A For EBITDA	2,207	2,319	2,310	1,835	1,882	1,921
EBIT	18,593	18,176	16,690	16,860	15,269	13,870
EBIT Margin	24.51%	25.93%	27.49%	29.27%	30.11%	30.23%
Effective Tax Rate	15.61%	17.34%	19.65%	20.24%	20.10%	24.05%
Revenue as Reported	-	-	-	57,598	50,703	45,876
Advertising Expenses	-	1,355	961.42	3.61	3.01	8.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.